JP2015120698A5 - - Google Patents

Download PDF

Info

Publication number
JP2015120698A5
JP2015120698A5 JP2014262319A JP2014262319A JP2015120698A5 JP 2015120698 A5 JP2015120698 A5 JP 2015120698A5 JP 2014262319 A JP2014262319 A JP 2014262319A JP 2014262319 A JP2014262319 A JP 2014262319A JP 2015120698 A5 JP2015120698 A5 JP 2015120698A5
Authority
JP
Japan
Prior art keywords
phenyl
propanoic acid
ethynyl
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014262319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015120698A (ja
JP6101675B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015120698A publication Critical patent/JP2015120698A/ja
Publication of JP2015120698A5 publication Critical patent/JP2015120698A5/ja
Application granted granted Critical
Publication of JP6101675B2 publication Critical patent/JP6101675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014262319A 2008-07-28 2014-12-25 代謝病の治療用の化合物 Expired - Fee Related JP6101675B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409808P 2008-07-28 2008-07-28
US61/084,098 2008-07-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011520437A Division JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物

Publications (3)

Publication Number Publication Date
JP2015120698A JP2015120698A (ja) 2015-07-02
JP2015120698A5 true JP2015120698A5 (enExample) 2017-01-05
JP6101675B2 JP6101675B2 (ja) 2017-03-22

Family

ID=41076693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011520437A Pending JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物
JP2014262319A Expired - Fee Related JP6101675B2 (ja) 2008-07-28 2014-12-25 代謝病の治療用の化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011520437A Pending JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物

Country Status (5)

Country Link
US (1) US8586607B2 (enExample)
EP (1) EP2313360B1 (enExample)
JP (2) JP2012503595A (enExample)
CN (2) CN102137836B (enExample)
WO (1) WO2010012650A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835750B (zh) 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
WO2010012650A1 (en) * 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20110201623A1 (en) 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN104470886A (zh) * 2011-04-08 2015-03-25 赛丹思科大学 用于治疗代谢疾病的邻-氟取代的化合物
SG10201603776RA (en) * 2011-05-04 2016-07-28 Univ Sydney Prenylated hydroxystilbenes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
EP3253745B1 (en) * 2015-02-05 2021-09-29 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019074241A1 (ko) * 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
MX2021003750A (es) * 2018-10-11 2021-06-15 Basf As Compuestos aromaticos y usos farmaceuticos de los mismos.
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US20240382465A1 (en) 2021-08-05 2024-11-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Aromatic acetylene derivative, and preparation method therefor and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
EP1787646A3 (en) * 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
NZ502582A (en) * 1997-07-31 2002-07-26 American Home Prod Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999029640A2 (en) * 1997-12-05 1999-06-17 Eisai Co., Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
US6284796B1 (en) * 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
US6518283B1 (en) * 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
JP5046466B2 (ja) * 2000-08-11 2012-10-10 科研製薬株式会社 ２，３−ジフェニルプロピオン酸誘導体またはその塩、それを用いた医薬および細胞接着阻害剤ならびにその使用方法
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
EP1559422B1 (en) * 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
CN1914173A (zh) * 2003-12-12 2007-02-14 惠氏公司 用于治疗心血管疾病的喹啉化合物
PE20050676A1 (es) * 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CA2583326A1 (en) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited Receptor function regulating agent
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
AU2007214709A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US20080221195A1 (en) 2006-12-13 2008-09-11 Lars Wortmann 1,2-diarylacetylene derivatives of acyltryptophanols
WO2010012650A1 (en) * 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases

Similar Documents

Publication Publication Date Title
JP2015508749A5 (enExample)
JP2016028068A5 (enExample)
JP2006511474A5 (enExample)
FI3555076T3 (fi) Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja
JP2016500063A5 (enExample)
JP2007504284A5 (enExample)
JP2019513804A5 (enExample)
JP2012532112A5 (enExample)
JP2012255002A5 (enExample)
JP6812564B2 (ja) 肝疾患治療剤
JP2012504141A5 (enExample)
CN102348689A (zh) 含有羟基和/或羧基的胺与作为dhodh抑制剂的胺基烟碱酸衍生物的加成盐
JP2004504301A5 (enExample)
JP2020502111A5 (enExample)
JP2010529203A5 (enExample)
JP2004506718A5 (enExample)
JP2004529161A5 (enExample)
AU2005220728A1 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2015517525A5 (enExample)
JP2013529637A5 (enExample)
RU2015113746A (ru) Замещенные сульфонамиды
JP2016510741A5 (enExample)
JP2019531346A (ja) 甲状腺関連副作用を低下させる方法
JP2007532511A5 (enExample)
JP2013510077A5 (enExample)